FY2024 EPS Estimates for RARE Decreased by Leerink Partnrs

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Leerink Partnrs reduced their FY2024 earnings estimates for shares of Ultragenyx Pharmaceutical in a note issued to investors on Tuesday, November 5th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharmaceutical company will earn ($6.31) per share for the year, down from their prior forecast of ($6.27). The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($6.29) per share. Leerink Partnrs also issued estimates for Ultragenyx Pharmaceutical’s Q4 2024 earnings at ($1.41) EPS, Q1 2025 earnings at ($1.47) EPS, Q2 2025 earnings at ($1.38) EPS, Q3 2025 earnings at ($1.33) EPS, Q4 2025 earnings at ($1.26) EPS, FY2025 earnings at ($5.44) EPS and FY2026 earnings at ($2.42) EPS.

Other research analysts have also issued reports about the stock. HC Wainwright raised their price objective on shares of Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $116.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday. Barclays decreased their price objective on Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating for the company in a report on Monday, August 5th. Wells Fargo & Company increased their price objective on Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Finally, TD Cowen lifted their target price on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $86.69.

Ultragenyx Pharmaceutical Stock Down 0.1 %

Shares of RARE opened at $50.36 on Friday. The business’s fifty day moving average is $55.06 and its 200 day moving average is $48.17. Ultragenyx Pharmaceutical has a 12-month low of $34.06 and a 12-month high of $60.37. The stock has a market cap of $4.64 billion, a P/E ratio of -7.78 and a beta of 0.58.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.45) by $0.05. The business had revenue of $139.49 million for the quarter, compared to analyst estimates of $135.28 million. Ultragenyx Pharmaceutical had a negative return on equity of 197.73% and a negative net margin of 106.93%. The company’s quarterly revenue was up 42.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($2.23) earnings per share.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Headlands Technologies LLC purchased a new stake in shares of Ultragenyx Pharmaceutical during the first quarter worth $28,000. nVerses Capital LLC bought a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at $33,000. UMB Bank n.a. lifted its holdings in Ultragenyx Pharmaceutical by 58.1% during the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 352 shares in the last quarter. Values First Advisors Inc. bought a new position in Ultragenyx Pharmaceutical in the 3rd quarter worth about $56,000. Finally, Capital Performance Advisors LLP bought a new position in Ultragenyx Pharmaceutical in the 3rd quarter worth about $107,000. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 7,465 shares of the stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the completion of the transaction, the chief financial officer now directly owns 92,301 shares of the company’s stock, valued at $4,869,800.76. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Howard Horn sold 7,465 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the sale, the chief financial officer now owns 92,301 shares of the company’s stock, valued at approximately $4,869,800.76. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Emil D. Kakkis sold 20,000 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the sale, the chief executive officer now directly owns 2,223,985 shares in the company, valued at approximately $124,209,562.25. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 27,556 shares of company stock worth $1,515,967 in the last ninety days. Company insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.